This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Diane K. Wysowski, PhD; Dianne L. Kennedy, RPh, MPH; Thomas P. Gross, MD, MPH

JAMA. 1990;263(16):2185-2188.

Abstract
Data from two pharmaceutical marketing research databases, the National Prescription Audit and the National Disease and Therapeutic Index, were used to study trends in outpatient use of cholesterol-lowering drugs in the United States from 1978 through 1988. Retail pharmacies dispensed an estimated 4.4 million prescriptions for cholesterol-lowering drugs in 1978. This declined to 2.6 million in 1983 and increased dramatically to nearly 13 million in 1988. This fivefold increase between 1983 and 1988 was accounted for primarily by the introduction and use of two new drugs, gemfibrozil and lovastatin, and, to a lesser extent, by the increasing use of some older drugs. In 1988, after 1 full year of marketing, lovastatin was the leading cholesterol-lowering drug, followed closely by gemfibrozil; both drugs are currently considered second-line agents. Clofibrate and dextrothyroxine, drugs that ranked first and second in 1978, declined to ranks of sixth and eighth out of eight in 1988. Cholestyramine, gemfibrozil, and lovastatin accounted for about 75% of all lipid-lowering prescriptions in 1988. From 1978 through 1988, an average 54% of individuals using cholesterol-lowering drugs were 60 years of age or older. The 13 million prescriptions for cholesterollowering drugs in 1988 represent a maximum estimate of 13 million treated individuals. This number compares with the 60 million Americans with high cholesterol levels who are candidates for dietary advice, and, if cholesterol levels do not improve, for combined diet and drug intervention.

(JAMA. 1990;263:2185-2188)

Author Affiliations
From the Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Food and Drug Administration, Rockville, Md.

Footnotes
This report contains the views of the authors, which are not necessarily the views of the Food and Drug Administration.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
Law et al.
BMJ 2003;326:1423.
ABSTRACT | FULL TEXT  

Disparities in the Diagnosis and Pharmacologic Treatment of High Serum Cholesterol by Race and Ethnicity: Data From the Third National Health and Nutrition Examination Survey
Nelson et al.
Arch Intern Med 2002;162:929-935.
ABSTRACT | FULL TEXT  

The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost
Goldman et al.
J Am Coll Cardiol 2001;38:1012-1017.
ABSTRACT | FULL TEXT  

Time Trends in the Use of Cholesterol-Lowering Agents in Older Adults: The Cardiovascular Health Study
Lemaitre et al.
Arch Intern Med 1998;158:1761-1768.
ABSTRACT | FULL TEXT  

Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality: An Overview of Randomized Trials
Hebert et al.
JAMA 1997;278:313-321.
ABSTRACT  

Cholesterol Screening Guidelines : Consensus, Evidence, and Common Sense
Garber and Browner
Circulation 1997;95:1642-1645.
FULL TEXT  

Carcinogenicity of Lipid-Lowering Drugs
Newman and Hulley
JAMA 1996;275:55-60.
ABSTRACT  

Evaluating Cholesterol Screening: The Importance of Controlling for Regression to the Mean
Forrow et al.
Arch Intern Med 1995;155:2177-2184.
ABSTRACT  

Why Aren't We Using More Niacin?
Felicetta and Hayden
Arch Fam Med 1994;3:324-326.
ABSTRACT  

Combination Drug Therapy for Hypercholesterolemia: The Trade-off Between Cost and Simplicity
Heudebert et al.
Arch Intern Med 1993;153:1828-1837.
ABSTRACT  

Recent Trends in the Identification and Treatment of High Blood Cholesterol by Physicians: Progress and Missed Opportunities
Giles et al.
JAMA 1993;269:1133-1138.
ABSTRACT  

General Internal Medicine
Stoeckle and Goodson
JAMA 1991;265:3123-3125.
ABSTRACT  

Costs and Health Consequences of Cholesterol Screening for Asymptomatic Older Americans
Garber et al.
Arch Intern Med 1991;151:1089-1095.
ABSTRACT  

Change in Cholesterol Awareness and Action: Results From National Physician and Public Surveys
Schucker et al.
Arch Intern Med 1991;151:666-673.
ABSTRACT  

Detection and Treatment of Elevated Blood Cholesterol: What Have We Learned?
Dalen
Arch Intern Med 1991;151:25-28.
ABSTRACT  

Myopathy and Rhabdomyolysis With Lovastatin Taken With Gemfibrozil
Goldstein
JAMA 1990;264:2991-2991.
ABSTRACT  

Reducing High Blood Cholesterol Level With Drugs: Cost-effectiveness of Pharmacologic Management
Schulman et al.
JAMA 1990;264:3025-3033.
ABSTRACT  

LOVASTATIN AND GEMFIBROZIL ARE NOW THE LEADING CHOLESTEROL-LOWERING DRUGS
JWatch General 1990;1990:6-6.
FULL TEXT